Starpharma Holdings Ltd (SPL) - Net Assets

Latest as of December 2025: AU$21.48 Million AUD ≈ $15.20 Million USD

Based on the latest financial reports, Starpharma Holdings Ltd (SPL) has net assets worth AU$21.48 Million AUD (≈ $15.20 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (AU$26.17 Million ≈ $18.51 Million USD) and total liabilities (AU$4.69 Million ≈ $3.32 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check SPL asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Key Net Assets Metrics

Metric	Value
Current Net Assets	AU$21.48 Million
% of Total Assets	82.08%
Annual Growth Rate	-1.66%
5-Year Change	-69.51%
10-Year Change	-61.56%
Growth Volatility	44.98

Starpharma Holdings Ltd - Net Assets Trend (2000–2025)

This chart illustrates how Starpharma Holdings Ltd's net assets have evolved over time, based on quarterly financial data. Also explore balance sheet size of Starpharma Holdings Ltd for the complete picture of this company's asset base.

Annual Net Assets for Starpharma Holdings Ltd (2000–2025)

The table below shows the annual net assets of Starpharma Holdings Ltd from 2000 to 2025. For live valuation and market cap data, see SPL company net worth.

Year	Net Assets	Change
2025-06-30	AU$19.00 Million ≈ $13.44 Million	-32.43%
2024-06-30	AU$28.12 Million ≈ $19.89 Million	-19.24%
2023-06-30	AU$34.81 Million ≈ $24.63 Million	-28.06%
2022-06-30	AU$48.39 Million ≈ $34.24 Million	-22.32%
2021-06-30	AU$62.30 Million ≈ $44.08 Million	+98.88%
2020-06-30	AU$31.33 Million ≈ $22.17 Million	-26.11%
2019-06-30	AU$42.40 Million ≈ $30.00 Million	-20.43%
2018-06-30	AU$53.28 Million ≈ $37.70 Million	-12.64%
2017-06-30	AU$60.98 Million ≈ $43.15 Million	+23.39%
2016-06-30	AU$49.42 Million ≈ $34.97 Million	+31.59%
2015-06-30	AU$37.56 Million ≈ $26.57 Million	+13.98%
2014-06-30	AU$32.95 Million ≈ $23.31 Million	-28.32%
2013-06-30	AU$45.97 Million ≈ $32.53 Million	-5.51%
2012-06-30	AU$48.65 Million ≈ $34.42 Million	+75.68%
2011-06-30	AU$27.69 Million ≈ $19.59 Million	-20.52%
2010-06-30	AU$34.84 Million ≈ $24.65 Million	+36.65%
2009-06-30	AU$25.50 Million ≈ $18.04 Million	+25.10%
2008-06-30	AU$20.38 Million ≈ $14.42 Million	-20.76%
2007-06-30	AU$25.72 Million ≈ $18.20 Million	+20.68%
2006-06-30	AU$21.32 Million ≈ $15.08 Million	+113.89%
2005-06-30	AU$9.97 Million ≈ $7.05 Million	-43.35%
2004-06-30	AU$17.59 Million ≈ $12.45 Million	+90.33%
2003-06-30	AU$9.24 Million ≈ $6.54 Million	-46.47%
2002-06-30	AU$17.27 Million ≈ $12.22 Million	-30.70%
2001-06-30	AU$24.92 Million ≈ $17.63 Million	-13.65%
2000-06-30	AU$28.85 Million ≈ $20.42 Million	--

Equity Component Analysis

This analysis shows how different components contribute to Starpharma Holdings Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have decreased by 24814102200.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (June 2025)

Component	Amount	Percentage
Common Stock	AU$240.75 Million	1267.24%
Other Comprehensive Income	AU$30.60 Million	161.07%
Total Equity	AU$19.00 Million	100.00%

Starpharma Holdings Ltd Competitors by Market Cap

The table below lists competitors of Starpharma Holdings Ltd ranked by their market capitalization.

Company	Market Cap
Sentral REIT KLSE:5123	$211.61 Million
eGain Corporation NASDAQ:EGAN	$211.69 Million
PRG Corporation Public Company Limited BK:PRG	$211.70 Million
Gemini Space Station, Inc. Class A Common Stock NASDAQ:GEMI	$211.73 Million
Sound Point Meridian Capital, Inc. NYSE:SPMC	$211.44 Million
Tureks Turizm Tasimacilik AS IS:TUREX	$211.41 Million
Ohio Valley Banc Corp NASDAQ:OVBC	$211.38 Million
Nova Minerals Ltd AU:NVA	$211.37 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Starpharma Holdings Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 28,116,000 to 18,998,000, a change of -9,118,000 (-32.4%).
Net loss of 9,990,000 reduced equity.
Other comprehensive income increased equity by 871,000.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	AU$-9.99 Million	-52.58%
Other Comprehensive Income	AU$871.00K	+4.58%
Other Changes	AU$1.00K	+0.01%
Total Change	AU$-	-32.43%

Book Value vs Market Value Analysis

This analysis compares Starpharma Holdings Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 15.59x
The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
The price-to-book ratio has increased from 2.19x to 15.59x over the analyzed period, suggesting growing market confidence.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2000-06-30	AU$0.32	AU$0.71	x
2001-06-30	AU$0.30	AU$0.71	x
2002-06-30	AU$0.19	AU$0.71	x
2003-06-30	AU$0.10	AU$0.71	x
2004-06-30	AU$0.17	AU$0.71	x
2005-06-30	AU$0.09	AU$0.71	x
2006-06-30	AU$0.16	AU$0.71	x
2007-06-30	AU$0.16	AU$0.71	x
2008-06-30	AU$0.11	AU$0.71	x
2009-06-30	AU$0.14	AU$0.71	x
2010-06-30	AU$0.15	AU$0.71	x
2011-06-30	AU$0.11	AU$0.71	x
2012-06-30	AU$0.18	AU$0.71	x
2013-06-30	AU$0.16	AU$0.71	x
2014-06-30	AU$0.12	AU$0.71	x
2015-06-30	AU$0.12	AU$0.71	x
2016-06-30	AU$0.14	AU$0.71	x
2017-06-30	AU$0.17	AU$0.71	x
2018-06-30	AU$0.14	AU$0.71	x
2019-06-30	AU$0.11	AU$0.71	x
2020-06-30	AU$0.08	AU$0.71	x
2021-06-30	AU$0.16	AU$0.71	x
2022-06-30	AU$0.12	AU$0.71	x
2023-06-30	AU$0.09	AU$0.71	x
2024-06-30	AU$0.07	AU$0.71	x
2025-06-30	AU$0.05	AU$0.71	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Starpharma Holdings Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): -52.58%
The company may be facing challenges in efficiently utilizing shareholder equity.
DuPont Analysis Breakdown:
• Net Profit Margin: -203.38%
• Asset Turnover: 0.19x
• Equity Multiplier: 1.34x
Recent ROE (-52.58%) is below the historical average (-30.44%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2000	-6.14%	-110.06%	0.06x	1.01x	AU$-4.66 Million
2001	-15.68%	-198.88%	0.08x	1.04x	AU$-6.40 Million
2002	0.31%	13.82%	0.02x	1.11x	AU$-1.65 Million
2003	-1.89%	-11.79%	0.14x	1.16x	AU$-1.10 Million
2004	-31.25%	-395.36%	0.08x	1.05x	AU$-7.26 Million
2005	-76.12%	-370.18%	0.16x	1.25x	AU$-8.58 Million
2006	-35.29%	-1504557.80%	0.00x	1.17x	AU$-9.65 Million
2007	-28.16%	-838.68%	0.03x	1.18x	AU$-9.82 Million
2008	-36.75%	-530.52%	0.06x	1.21x	AU$-9.53 Million
2009	-16.18%	-204.41%	0.07x	1.13x	AU$-6.68 Million
2010	-18.30%	-454.27%	0.04x	1.08x	AU$-9.86 Million
2011	-32.25%	-780.59%	0.04x	1.08x	AU$-11.70 Million
2012	-28.07%	-1476.54%	0.02x	1.12x	AU$-18.52 Million
2013	-11.38%	-26145.00%	0.00x	1.06x	AU$-9.83 Million
2014	-44.41%	-1168.00%	0.03x	1.12x	AU$-17.93 Million
2015	-50.46%	-1116.68%	0.04x	1.18x	AU$-22.71 Million
2016	-43.08%	-465.50%	0.08x	1.19x	AU$-26.23 Million
2017	-24.95%	-417.25%	0.05x	1.09x	AU$-21.32 Million
2018	-19.30%	-207.48%	0.08x	1.10x	AU$-15.61 Million
2019	-33.62%	-524.04%	0.06x	1.15x	AU$-18.49 Million
2020	-46.86%	-243.30%	0.15x	1.25x	AU$-17.81 Million
2021	-31.67%	-1097.44%	0.02x	1.18x	AU$-25.96 Million
2022	-33.38%	-345.02%	0.07x	1.37x	AU$-20.99 Million
2023	-44.92%	-532.09%	0.06x	1.50x	AU$-19.12 Million
2024	-29.04%	-98.50%	0.23x	1.31x	AU$-10.98 Million
2025	-52.58%	-203.38%	0.19x	1.34x	AU$-11.89 Million

Industry Comparison

This section compares Starpharma Holdings Ltd's net assets metrics with peer companies in the Biotechnology industry.

Industry Context

Industry: Biotechnology
Average net assets among peers: $6,848,959
Average return on equity (ROE) among peers: -317.22%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Starpharma Holdings Ltd (SPL)	AU$21.48 Million	-6.14%	0.22x	$211.46 Million
Adalta Ltd (1AD)	$705.89K	-185.28%	0.37x	$8.12 Million
Algorae Pharmaceuticals Ltd (1AI)	$8.43 Million	-80.40%	0.15x	$20.04 Million
ACRUX Ltd (ACR)	$3.28 Million	-177.05%	1.74x	$3.49 Million
Actinogen Medical Ltd (ACW)	$346.99K	-440.69%	0.34x	$103.45 Million
Argenica Therapeutics Ltd (AGN)	$18.40K	-2084.05%	19.53x	$15.45 Million
Arovella Therapeutics Ltd (ALA)	$15.99 Million	-12.83%	0.27x	$66.62 Million
Anatara Lifesciences Ltd (ANR)	$-280.65K	0.00%	0.00x	$1.57 Million
Alterity Therapeutics Ltd (ATH)	$31.37 Million	-24.64%	0.08x	$80.80 Million
Amplia Therapeutics Ltd (ATX)	$5.98 Million	-67.99%	0.37x	$54.45 Million
Avecho Biotechnology Ltd (AVE)	$2.65 Million	-99.27%	0.26x	$31.19 Million

About Starpharma Holdings Ltd

AU:SPL Australia Biotechnology

Market Cap

$211.46 Million

AU$298.86 Million AUD

Market Cap Rank

#16323 Global

#463 in Australia

Share Price

AU$0.71

Change (1 day)

-2.74%

52-Week Range

AU$0.09 - AU$0.75

All Time High

AU$2.49